RESUMO
Endogenous intoxication and immune insufficiency accompany neoplastic process. Complex therapy for cancer worsens these pathologic conditions by its adverse effects (AE) and thus complicates treatment. Efferent therapy can provide continuity of antineoplastic therapy with normalization of hemostasis and decreasing the rate of AE and their intensity. Efferent therapy meaningfully increases patient's quality of life and decreases the needed drug support when used as a part of complex therapy. Proper use of efferent therapy can markedly increase efficacy of surgical treatment, radiation therapy and drug therapy.
Assuntos
Antineoplásicos/efeitos adversos , Terapia Combinada/métodos , Hemoperfusão , Neoplasias/tratamento farmacológico , Plasmaferese , Antineoplásicos/administração & dosagem , Institutos de Câncer/tendências , Terapia Combinada/tendências , Hemoperfusão/métodos , Humanos , Neoplasias/terapia , Plasmaferese/métodos , Qualidade de Vida , Federação Russa , Desintoxicação por Sorção/métodosRESUMO
Soft tissue sarcomas (STS) comprise a heterogeneous group of rare malignancies from mesenchymal tissues. The biology of STS causes high aggressiveness, poor prognosis due to early development of distant metastases and limited chemotherapeutic options due to tumor resistance. The paper considers the current principles of chemotherapy for early and metastatic disease. Results of own experience of advanced STS patients' treatment are presented and discussed.